> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# ‘Breakthrough’ for Central Venous Oxygenation Monitor
- URL: https://www.fdaweb.com/breakthrough-for-central-venous-oxygenation-monitor/
- Published: 2022-02-23T12:00:00.000Z
- Updated: 2026-09-14T17:33:44.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5151227

FDA has granted Noninvasix a breakthrough device designation for its LivOx Central Venous Oxygenation Monitor for real-time, continuous or spot monitoring of central venous oxygen saturation (ScvO2) in adults at risk of septic shock. “Measuring ScvO2 non-invasively will open new paths to more efficient and earlier diagnosis of septic shock, enabling better patient care and reducing healthcare costs,” the company says.

The device comprises a disposable patient interface, reusable probe, data display and hardware. Noninvasix says the probe can be worn on the patient’s chest to continuously monitor venous oxygen saturation levels in real time. The device can also be used to target specific blood vessels based on the desired metric, it says.